Sunday, September 13, 2026

Venture Capital & Funding

2 articles

Venture Capital Creates 68 Unicorns in Q1 2026, Matching 58% of 2025 Full-Year Total

Venture Capital Creates 68 Unicorns in Q1 2026, Matching 58% of 2025 Full-Year Total

The venture capital market generated 68 new unicorns in Q1 2026, already surpassing 2024's annual count of 117 and approaching 2025's 187. February 2026 recorded the highest venture funding levels on record, with specialized healthcare and biotech firms leading strategic deployments alongside strong exits from generalist portfolios.

LM Salvado
Jaunt Air Mobility Faces Capital Runway Crisis as eVTOL Certification Costs Mount

Jaunt Air Mobility Faces Capital Runway Crisis as eVTOL Certification Costs Mount

Jaunt Air Mobility confronts high-probability capital depletion before commercialization, threatening its position in the advanced air mobility sector. The eVTOL manufacturer must raise additional funds amid challenging market conditions for aerospace startups. The capital crunch reflects broader funding pressures across the electric aviation industry.

ViaNews Editorial Team (Finance)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com